ERBB2 and non-small cell lung carcinoma: The four phase 2 studies and one phase 1 study in patients with HER2-positive or mutated NSCLC are ongoing: the DESTINY-Lung01 (NCT03505710), and the DESTINY-Lung02 (NCT04644237) evaluate T-DXd as monotherapy, while the DESTINY-Lung03 (NCT04686305), and the HUDSON trial (NCT03334617) investigate the combination of T-DXd with immunotherapy, chemotherapy, and novel anticancer agents.